- AtomVie Global Radiopharma has supplied the first patient dose of Ariceum Therapeutics’ 225Ac-SSO110 for the Phase 1/2 SANTANA-225 trial.
- The company is providing cGMP manufacturing and supply of the radiopharmaceutical therapy under a CDMO partnership.
AtomVie Global Radiopharma (AtomVie), a radiopharmaceutical contract development and manufacturing organisation, has supplied the first clinical dose of Ariceum Therapeutics’ 225Ac-SSO110. The therapy, an Actinium-225-labelled antagonist targeting somatostatin type 2 receptors, is being evaluated in Ariceum’s Phase 1/2 SANTANA-225 trial for extensive-stage small cell lung cancer and Merkel cell carcinoma.
The collaboration enables AtomVie to use its cGMP facilities and technical expertise to support the production of 225Ac-SSO110. According to the press release, the partnership aims to ensure consistent supply and quality throughout the clinical study as Ariceum advances the therapy through development.
“We are honored to partner with Ariceum to deliver the critical supply of 225Ac-SSO110 for the SANTANA-225 clinical trial. Our mission of transforming patients’ lives with high quality radiopharmaceuticals drives every step of our work.”
Bruno Paquin, chief executive officer of AtomVie
Manuel Sturzbecher-Höhne, chief technology officer of Ariceum Therapeutics, noted the milestone represented by dosing the first patient and highlighted AtomVie’s commitment to manufacturing quality as the therapy progresses through clinical evaluation.
The partnership combines AtomVie’s CDMO capabilities with Ariceum’s development programme to support the advancement of 225Ac-SSO110 as a potential treatment option for aggressive and underserved cancers.
